BENEFIT-RISK ANALYSIS OF ADALIMUMAB AND ALTERNATIVE TREATMENTS FOR MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS

被引：0
|
作者：
Hicks, K. A. [1 ]
Earnshaw, S. R. [1 ]
Shaw, J. W. [2 ]
Cifaldi, M. [2 ]
机构：
[1] RTI Hlth Solut, Res Triangle Pk, NC USA
[2] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 07期
关键词：
D O I：
10.1016/j.jval.2012.08.1360
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A439 / A440
页数：2
相关论文
共 50 条
  • [21] Benefit-risk profile of tofacitinib in patients with moderate-to-severe chronic plaque psoriasis: pooled analysis across six clinical trials
    Strober, B. E.
    Gottlieb, A. B.
    van de Kerkhof, P. C. M.
    Puig, L.
    Bachelez, H.
    Chouela, E.
    Imafuku, S.
    Thaci, D.
    Tan, H.
    Valdez, H.
    Gupta, P.
    Kaur, M.
    Frajzyngier, V.
    Wolk, R.
    BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (01) : 67 - 75
  • [22] Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis
    Weinblatt, Michael E.
    Baranauskaite, Asta
    Niebrzydowski, Jaroslaw
    Dokoupilova, Eva
    Zielinska, Agnieszka
    Jaworski, Janusz
    Racewicz, Artur
    Pileckyte, Margarita
    Jedrychowicz-Rosiak, Krystyna
    Cheong, Soo Yeon
    Ghil, Jeehoon
    ARTHRITIS & RHEUMATOLOGY, 2018, 70 (01) : 40 - 48
  • [23] Study on the frequency and risk factors of moderate-to-severe sleep apnea syndrome in rheumatoid arthritis
    Mutoh, Tomoyuki
    Okuda, Yasuaki
    Mokuda, Sho
    Sawada, Naoya
    Matoba, Kenichiro
    Yamada, Akihiro
    Jouyama, Kazuo
    Onishi, Makoto
    Takasugi, Kiyoshi
    MODERN RHEUMATOLOGY, 2016, 26 (05) : 681 - 684
  • [24] The role of upadacitinib in the treatment of moderate-to-severe active rheumatoid arthritis
    Avci, Ali Berkant
    Feist, Eugen
    Burmester, Gerd Rudiger
    THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE, 2021, 13
  • [25] Cost-effectiveness of abatacept for moderate-to-severe rheumatoid arthritis
    Tsao, Nicole W.
    Shojania, Kam
    Marra, Carlo A.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (01) : 9 - 18
  • [26] Long-Term Benefit–Risk Profiles of Treatments for Moderate-to-Severe Plaque Psoriasis: A Network Meta-Analysis
    April W. Armstrong
    Ahmed M. Soliman
    Keith A. Betts
    Yan Wang
    Yawen Gao
    Vassilis Stakias
    Luis Puig
    Dermatology and Therapy, 2022, 12 : 167 - 184
  • [27] Where are we with the benefit-risk ratio of JAK inhibitors in rheumatoid arthritis?
    Avouac, Jerome
    JOINT BONE SPINE, 2022, 89 (06)
  • [28] TOCILIZUMAB IN MODERATE-TO-SEVERE RHEUMATOID ARTHRITIS: SYSTEMATIC REVIEW OF EFFICACY AND SAFETY
    Nadzieja-Koziol, A.
    Leszczynska, D.
    Kowalczyk, M.
    Malysiak-Szpond, S.
    VALUE IN HEALTH, 2019, 22 : S240 - S240
  • [29] A modeling framework for the economic evaluation of baricitinib in moderate-to-severe rheumatoid arthritis
    Schlueter, Max
    Rouse, Peter
    Pitcher, Ashley
    Graham-Clarke, Peita Louise
    Nicolay, Claudia
    Fakhouri, Walid
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2020, 20 (02) : 221 - 228
  • [30] Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis
    Soriano, Enrique R.
    Dellepiane, Analia
    Salvatierra, Gabriela
    Alejandro Benitez, Cristian
    Garcia Salinas, Rodrigo
    Baruzzo, Carlos
    FUTURE SCIENCE OA, 2018, 4 (04):
12345